吡格列酮对2型糖尿病肾病患者血清AGE-肽和MCP-1的影响

目的 探讨吡格列酮对2型糖尿病肾病患者血清糖基化终产物-肽（AGE-肽）和单核细胞趋化蛋白-1（MCP-1）水平的影响。方法 2型糖尿病伴微量白蛋白尿患者60例，分别接受格列吡嗪控释片（瑞易宁）和吡格列酮治疗6个月。流动注射分析法检测血清AGE-肽，EUSA法检测血清MCP-1。结果 两组患者治疗后血清AGE-肽均较治疗前下降，吡格列酮组明显低于瑞易宁组；吡格列酮组治疗后血清MCP-1较治疗前明显下降，且明显低于瑞易宁组；吡格列酮组治疗后尿白蛋白／肌酐下降值与血清AGE-肽和MCP-1下降值呈明显正相关。结论 吡格列酮降低糖尿病。肾病患者血清AGE-肽和MCP-1水平，可能通过抗炎抗糖基化机制发挥肾保护效应。

Effect of pioglitazone on serum advanced glycosylation end product peptide and monocyte chemoattractant protein-1 in type 2 diabetic patients

Objective To investigate the effect of pioglitazone on serum advanced glycosylation end products-peptide(AGE-P) and monocyte chemoattractant protein-1(MCP-1) in the patients with type 2 diabetic nephropathy.Methods Sixty type 2 diabetic patients with microalbuminuria were randomized to receive pioglitazone or glipizide XL treatment for 6 months.Serum AGE-P and MCP-1 were measured by flow injection assay and ELISA respectively.Results Serum AGE-P was significantly lower after treatment in both groups than that before treatment,while it was significantly lower in pioglitazone group than that in glipizide XL group.Serum MCP-1 was significantly reduced in pioglitazone group.Conclusion Pioglitazone reduces serum AGE-P and MCP-1 levels elevated in type 2 diabetic patients with diabetic nephropathy and suggests that pioglitazone might play reno-protection role via suppression of glycosylation and inflammation.